2019
DOI: 10.1080/24734306.2019.1572268
|View full text |Cite
|
Sign up to set email alerts
|

Poor outcomes after dabigatran-associated intracranial hemorrhage despite idarucizumab reversal

Abstract: Intracranial hemorrhage (ICH) is the most deadly bleeding complication associated with anticoagulation. The efficacy of idarucizumab in treating dabigatran-associated ICH in the real world is uncertain. We sought to assess patient outcomes in this sick population. This was a 2-year prospective observational study of functional neurologic status in patients who received idarucizumab following dabigatran-associated ICH across three tertiary Canadian hospitals. The primary outcome was disability on the modified R… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 7 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?